DNA Mismatch Repair
Showing 1 - 25 of 9,160
MSI-H Colorectal Cancer Trial (colorectal resection)
Completed
- MSI-H Colorectal Cancer
- colorectal resection
- (no location specified)
May 22, 2023
Colorectal Cancer Trial in Beijing (IBI310 (anti-CTLA-4 antibody), Sintilimab(anti-PD-1 antibody))
Active, not recruiting
- Colorectal Cancer
- IBI310 (anti-CTLA-4 antibody)
- Sintilimab(anti-PD-1 antibody)
-
Beijing, ChinaBeijing cancer hospital
Sep 15, 2022
Endometrial Adenocarcinoma, Endometrial Carcinoma, Lynch Syndrome Trial in United States (Genetic Counseling, Genetic Testing,
Active, not recruiting
- Endometrial Adenocarcinoma
- +3 more
- Genetic Counseling
- +3 more
-
Akron, Ohio
- +8 more
Dec 2, 2022
MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers Trial in Kashiwa (HRO761,
Recruiting
- MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers
- HRO761
- +2 more
-
Kashiwa, Chiba, JapanNovartis Investigative Site
May 2, 2023
Metastatic Colorectal Cancer Trial in China (HX008, Investigator's Choice Chemotherapy)
Not yet recruiting
- Metastatic Colorectal Cancer
- HX008
- Investigator's Choice Chemotherapy
-
Hefei, Anhui, China
- +9 more
Dec 8, 2022
Lynch Syndrome Trial in United States (Laboratory Biomarker Analysis, Naproxen, Placebo Administration)
Completed
- Lynch Syndrome
- Laboratory Biomarker Analysis
- +2 more
-
Boston, Massachusetts
- +3 more
Jan 22, 2021
Endometrial Tumors, Endometrial Cancer Trial in Seoul (Nivolumab)
Not yet recruiting
- Endometrial Neoplasms
- Endometrial Cancer
-
Seoul, Korea, Republic ofSeverance Hospital, Yonsei University Health System
Mar 21, 2023
Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Proficient Mismatch Repair Trial in China (S1,
Not yet recruiting
- Adenocarcinoma of the Stomach
- +2 more
- S1
- +3 more
-
Hangzhou, Zhejiang, China
- +4 more
May 23, 2023
Stage I Colon Cancer, Stage II Colon Cancer, Stage III Colon Cancer Trial in Houston (Tecentriq 1200 MG in 20 ML Injection +
Not yet recruiting
- Stage I Colon Cancer
- +2 more
- Tecentriq 1200 MG in 20 ML Injection + Capecitabine 1000 mg/m2 + Oxaliplatin 130 mg/m2
- +2 more
-
Houston, TexasBaylor College of Medicine
May 22, 2023
Recurrent Endometrial Cancer, Solid Tumors Trial in Pittsburgh (pembrolizumab, Sitravatinib)
Recruiting
- Recurrent Endometrial Cancer
- Solid Tumors
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Sep 12, 2022
Colorectal Carcinoma Trial (mFOLFOX6, FOLFIRI, pembrolizumab)
Afamelanotide Evaluated as Skin DNA Repair Therapy in Healthy Volunteers Trial in Clinuvel Investigational Site (Afamelanotide)
Recruiting
- Afamelanotide Evaluated as Skin DNA Repair Therapy in Healthy Volunteers
-
Clinuvel Investigational Site, United KingdomCLINUVEL Investigational Site
Nov 9, 2022
Locally Advanced Malignant Solid Tumor Trial in Houston (Pembrolizumab)
Recruiting
- Locally Advanced Malignant Solid Neoplasm
- Pembrolizumab
-
Houston, TexasM D Anderson Cancer Center
Mar 22, 2022
Adenocarcinoma - GEJ, Gastric Adenocarcinoma Trial (Dostarlimab)
Not yet recruiting
- Adenocarcinoma - GEJ
- Gastric Adenocarcinoma
- (no location specified)
Sep 26, 2023
Metastatic Malignant Solid Tumor, Unresectable Malignant Solid Tumor Trial (Biopsy, Diagnostic Imaging, Novobiocin Sodium)
Not yet recruiting
- Metastatic Malignant Solid Neoplasm
- Unresectable Malignant Solid Neoplasm
- Biopsy
- +2 more
- (no location specified)
Jan 14, 2023
Recurrent Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma Trial in
Recruiting
- Recurrent Endometrial Adenocarcinoma
- +8 more
- Ipilimumab
- Nivolumab
-
Iowa City, Iowa
- +9 more
Jan 27, 2023
Epstein-Barr Virus Positive, Gastric Adenocarcinoma, Mismatch Repair Protein Deficiency Trial in New Brunswick (drug, other,
Recruiting
- Epstein-Barr Virus Positive
- +10 more
- Capecitabine
- +3 more
-
Atlanta, Georgia
- +2 more
Dec 10, 2022
Anal Squamous Cell Carcinoma, Colorectal Tumors, Soft Tissue Sarcoma Trial (Regorafenib in combination with Tislelizumab)
Not yet recruiting
- Anal Squamous Cell Carcinoma
- +7 more
- Regorafenib in combination with Tislelizumab
- (no location specified)
Oct 12, 2022
Endometrial Cancer, Mismatch Repair-Proficient, Recurrent Endometrial Cancer Trial in Richmond (Lenvatinib, Pembrolizumab)
Recruiting
- Endometrial Cancer
- +2 more
-
Richmond, VirginiaVirginia Commonwealth University
Apr 5, 2022
Natural History Study for DNA Repair Disorders
Not yet recruiting
- DNA Repair Disorder
- +3 more
- Interval History
- +4 more
-
Minneapolis, MinnesotaUniversity of Minnesota- Twin Cities
Aug 8, 2022
Examination of Clinical and Laboratory Abnormalities in
Recruiting
- Cockayne Syndrome
- +4 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 25, 2023
Registry Study in MSI/dMMR Solid Tumors
Not yet recruiting
- DMMR Cancer
- +2 more
- (no location specified)
Aug 21, 2023
Castration Resistant Prostatic Cancer, Metastatic Prostate Cancer Trial in San Francisco (Pembrolizumab, Chemotherapy)
Active, not recruiting
- Castration Resistant Prostatic Cancer
- Metastatic Prostate Cancer
-
San Francisco, CaliforniaUniversity of California, San Francisco
May 17, 2022
Metastatic Solid Tumor, BRCA1 Mutation, BRCA2 Mutation Trial in San Francisco (Niraparib, Irinotecan)
Not yet recruiting
- Metastatic Solid Tumor
- +4 more
-
San Francisco, CaliforniaUniversity of California, San Francisco
Jan 12, 2023